Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. (17th September 2020)

• Record Type: Journal Article
• Authors: Falcone, Marco; Tiseo, Giusy; Nicastro, Manuela; Leonildi, Alessandro; Vecchione, Alessandra; Casella, Costanza; Forfori, Francesco; Malacarne, Paolo; Guarracino, Fabio; Barnini, Simona; Menichetti, Francesco
• Is Part Of: Clinical infectious diseases. Volume 72:Number 11(2021)
• Page Start: 2021
• Page End: 2024
• Publication Date: 2020-09-17
• Subjects: cefiderocol -- ICU -- Acinetobacter baumannii -- metallo-β-lactamases -- NDM-producing Klebsiella pneumoniae; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1410
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase–producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.